Clinical Report: Alterations in Peripheral Blood Lymphocyte Subpopulations as Predictors

Overview

This study identifies specific peripheral blood lymphocyte subsets as potential predictive biomarkers for immune checkpoint inhibitor efficacy and overall survival in metastatic osteosarcoma. Elevated levels of CD3−CD56+ and CD8+HLA-DR+ cells post-ICI treatment correlate with improved patient outcomes.

Background

Osteosarcoma is the most common primary malignant bone tumor in children and adolescents, with a poor prognosis for metastatic cases. The advent of immune checkpoint inhibitors (ICIs) has transformed cancer treatment, yet their effectiveness in metastatic osteosarcoma remains limited and unpredictable. Identifying reliable predictive biomarkers is crucial for optimizing treatment strategies and improving patient outcomes.

Data Highlights

Key Findings

• Pre-ICIs CD8+HLA-DR+ cells are protective indicators for overall survival.
• Post-ICIs CD3−CD56+, CD3+CD4+, and CD8+HLA-DR+ cells correlate with improved treatment response.
• Dynamic increases in CD3−CD56+ and CD8+HLA-DR+ cells post-ICIs significantly correlate with better outcomes.
• Patients with higher counts of CD45+, CD3−CD56+, CD4+HLA-DR+, CD3+CD8+, and CD8+HLA-DR+ at diagnosis had better disease control rates.
• Extrapulmonary metastasis is a significant risk factor for poor overall survival.

Clinical Implications

The identification of specific lymphocyte subsets as predictive biomarkers may guide treatment decisions for patients with metastatic osteosarcoma receiving ICIs. Monitoring these immune cell populations could help personalize therapy and improve patient outcomes.

Conclusion

This study highlights the potential of peripheral blood lymphocyte subsets as non-invasive biomarkers for predicting the efficacy of ICIs in metastatic osteosarcoma. Further research is needed to validate these findings in larger cohorts.

Related Resources & Content

1. Wu et al, Nature Communications, 2020 -- Immunogenomic Profiling of Osteosarcoma
2. Andersen et al, Annals of Oncology, 2018 -- Activity of T Cells in Metastatic Melanoma Resistant to Immune Checkpoint Inhibitor Treatment
3. Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf
4. The ASCO Post — Activity of T Cells in Metastatic Melanoma Resistant to Immune Checkpoint Inhibitor Treatment
5. The ASCO Post — Predictive Models for Outcomes With Immune Checkpoint Inhibitor Treatment in Metastatic Melanoma
6. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028)
7. Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies
8. Osteosarcoma and Undifferentiated Pleomorphic Sarcoma of Bone Treatment (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf